{"drugs":["Activase","Alteplase, Recombinant","Cathflo Activase"],"mono":{"0":{"id":"20930-s-0","title":"Generic Names","mono":"Alteplase, Recombinant"},"1":{"id":"20930-s-1","title":"Dosing and Indications","sub":{"0":{"id":"20930-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acute myocardial infarction:<\/b> 90-minute infusion, weight more than 67 kg: 15 mg IV bolus, followed by 50 mg IV infusion over 30 minutes, then 35 mg IV infusion over the next 60 minutes; total dose not to exceed 100 mg<\/li><li><b>Acute myocardial infarction:<\/b> 90-minute infusion, weight 67 kg or less: 15 mg IV bolus, followed by 0.75 mg\/kg IV infusion over 30 minutes, then 0.5 mg\/kg IV infusion over the next 60 minutes; total dose not to exceed 100 mg<\/li><li><b>Acute myocardial infarction:<\/b> 3-hour infusion, weight 65 kg or more: 60 mg IV the first hour (6 to 10 mg IV bolus followed by 50 to 54 mg IV infusion over the rest of the first hour), then 20 mg IV infusion the second hour, then 20 mg IV infusion the third hour; total dose not to exceed 100 mg<\/li><li><b>Acute myocardial infarction:<\/b> 3-hour infusion, weight less than 65 kg: 0.075 mg\/kg IV bolus, then 0.675 mg\/kg IV infusion for the remainder of the first hour, then 0.25 mg\/kg IV infusion the second hour, then 0.25 mg\/kg IV infusion the third hour; total dose not to exceed 100 mg<\/li><li><b>Arterial thrombosis:<\/b> Activase(R), 1.5 mg\/hour by transcatheter intra-arterial infusion until lysis of thrombus<\/li><li><b>Cerebrovascular accident, acute, Ischemic:<\/b> 0.9 mg\/kg IV, with 10% of the total dose administered IV bolus over the first minute, and then the remainder administered IV infusion over 60 minutes; MAX total dose, 90 mg; administer as soon as possible and within 3 hours after onset of symptoms<\/li><li><b>Pregnancy - Prosthetic cardiac valve thrombosis:<\/b> 25 mg IV over 6 hours; may repeat every 24 hours as needed for up to 6 total doses; MAX total dose, 150 mg (study dosing); immediately afterward, administer heparin 70 international units\/kg IV bolus followed by 16 international units\/kg IV infusion (MAX 1000 units\/hr) targeting aPTT of 1.5 to 2 times control; hold heparin prior to and during subsequent alteplase infusions<\/li><li><b>Pulmonary embolism:<\/b> 100 mg IV infused over 2 hours; initiate parenteral anticoagulation near the end of or immediately after alteplase infusion, once PTT or thrombin time is 2 times normal or lower<\/li><li><b>Venous catheter occlusion, Central:<\/b> Cathflo(R) Activase(R), (30 kg or greater) 2 mg\/ 2 mL instilled into occluded catheter; up to 2 doses may be used, separated by 120 minutes<\/li><li><b>Venous catheter occlusion, Central:<\/b> Cathflo(R) Activase(R), (less than 30 kg) dose equal to 110% of catheter lumen volume, MAX 2 mg in 2 mL; up to 2 doses may be used, separated by 120 minutes<\/li><li><b>Venous catheter occlusion, Central, Hemodialysis; Prophylaxis:<\/b> Alteplase 1 mg (with saline to fill the lock to the full volume of the lumen volume) in each lumen once weekly as the catheter-locking solution with heparin used in the other 2 sessions compared with patients that received heparin (5000 units\/mL, full lumenal volume) three times weekly was associated with less catheter malfunction and less bacteremia in a multicenter, randomized, blinded, controlled trial<\/li><\/ul>"},"1":{"id":"20930-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Arterial thrombosis:<\/b> 0.1 to 0.6 mg\/kg\/hour IV for 6 hours has been used, optimal doses are unknown; administer plasminogen (fresh frozen plasma) as needed prior to initiation of therapy<\/li><li><b>Venous catheter occlusion, Central:<\/b> Cathflo(R) Activase(R), (30 kg or greater) 2 mg\/ 2 mL instilled into occluded catheter; up to 2 doses may be used, separated by 120 minutes<\/li><li><b>Venous catheter occlusion, Central:<\/b> Cathflo(R) Activase(R), (less than 30 kg) dose equal to 110% of catheter lumen volume, MAX 2 mg in 2 mL; up to 2 doses may be used, separated by 120 minutes<\/li><\/ul>"},"3":{"id":"20930-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acute myocardial infarction<\/li><li>Cerebrovascular accident, acute, Ischemic<\/li><li>Pulmonary embolism<\/li><li>Venous catheter occlusion, Central<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Arterial thrombosis<\/li><li>Arteriovenous fistula thrombosis<\/li><li>Intracerebral hemorrhage, intraventricular<\/li><li>Pregnancy - Prosthetic cardiac valve thrombosis<\/li><li>Subarachnoid hemorrhage<\/li><li>Surgical procedure on eye proper<\/li><li>Vascular graft occlusion<\/li><li>Venous catheter occlusion, Central, Hemodialysis; Prophylaxis<\/li><li>Venous thromboembolism<\/li><\/ul>"}}},"3":{"id":"20930-s-3","title":"Contraindications\/Warnings","sub":[{"id":"20930-s-3-9","title":"Contraindications","mono":"<ul><li>Active internal bleeding<\/li><li>Current intracranial hemorrhage<\/li><li>Intracranial neoplasm, arteriovenous malformation, aneurysm, or other conditions that may increase the risk of bleeding<\/li><li>Bleeding diathesis<\/li><li>Recent (ie, within 3 months) intracranial or intraspinal surgery<\/li><li>Recent (ie, within 3 months) serious head trauma<\/li><li>Recent (ie, within 3 months) stroke, for patients with acute myocardial infarction or pulmonary embolism<\/li><li>Severe uncontrolled hypertension<\/li><li>Subarachnoid hemorrhage<\/li><\/ul>"},{"id":"20930-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Acute pericarditis or subacute bacterial endocarditis increase the risk of adverse effects<\/li><li>-- Patients with high likelihood of left-heart thrombus are at an increased risk of adverse effects<\/li><li>-- Hypertensive patients (systolic, 175 mmHg or greater; diastolic, 110 mmHg or greater) are at an increased risk of adverse effects<\/li><li>-- Stroke risk may outweigh treatment benefit in myocardial infarction patients at low risk of cardiac death<\/li><li>Endocrine and Metabolic:<\/li><li>-- Cholesterol embolism has been reported with thrombolytic agents<\/li><li>Gastrointestinal:<\/li><li>-- Recent gastrointestinal bleeding increases the risk of alteplase adverse effects<\/li><li>Hematologic:<\/li><li>-- Fatal hemorrhage associated with traumatic intubation has occurred<\/li><li>-- If treatment is initiated before coagulation test results are available, discontinue if baseline INR or aPTT elevations are seen<\/li><li>-- Carefully monitor for bleeding with concurrent anticoagulant therapy, especially at arterial puncture sites, and discontinue if serious bleeding develops<\/li><li>--Active internal bleeding or embolic complications may occur with venous catheter occlusion<\/li><li>-- Internal (ie, intracranial, retroperitoneal, gastrointestinal, genitourinary, respiratory) or external bleeding have been reported; discontinue use if serious bleeding occurs<\/li><li>-- Serious bleeding at critical location can occur; discontinue use<\/li><li>-- Septic thrombophlebitis increases the risk of adverse effects<\/li><li>-- An occluded AV cannula at a seriously infected site increases the risk of adverse effects<\/li><li>-- Hemostatic defects, including defects secondary to severe renal or hepatic disease, increase the risk of adverse effects<\/li><li>-- Underlying DVT may not be adequately treated in pulmonary embolism patients<\/li><li>-- Increased risk of re-embolization due to lysis of underlying DVT in pulmonary embolism patients<\/li><li>-- Minimize arterial and venous punctures due to an increased risk of bleeding; discontinue use if serious bleeding occurs<\/li><li>-- Thrombocytopenia<\/li><li>Hepatic:<\/li><li>-- Significant hepatic dysfunction increases the risk of adverse effects<\/li><li>Immunologic:<\/li><li>-- Catheter infection may occur with venous catheter occlusion<\/li><li>Neurologic:<\/li><li>-- Cerebrovascular disease increases the risk of adverse effects<\/li><li>Ophthalmic:<\/li><li>-- Hemorrhagic ophthalmic conditions, including diabetic hemorrhagic retinopathy, increase the risk of adverse effects<\/li><li>Renal:<\/li><li>-- Recent genitourinary bleeding increases the risk of adverse effects<\/li><li>Reproductive:<\/li><li>-- Pregnancy may increase the risk of adverse effects<\/li><li>-- Recent genitourinary bleeding may increase the risk of adverse effects<\/li><li>Other:<\/li><li>-- Orolingual angioedema has been reported in patients with ischemic stroke or myocardial infarction; monitoring recommended and discontinue if condition occurs<\/li><li>-- Avoid noncompressible arterial, internal jugular, or subclavian punctures or IM injection<\/li><li>-- Recent major surgery increases the risk of adverse effects<\/li><li>-- Recent trauma or advanced age (75 years or older) increases the risk of adverse effects<\/li><\/ul>"},{"id":"20930-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"20930-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"20930-s-4","title":"Drug Interactions","sub":{"1":{"id":"20930-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Acenocoumarol (theoretical)<\/li><li>Anistreplase (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (theoretical)<\/li><li>Argatroban (theoretical)<\/li><li>Aspirin (theoretical)<\/li><li>Benazepril (established)<\/li><li>Bivalirudin (theoretical)<\/li><li>Captopril (established)<\/li><li>Certoparin (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Clopidogrel (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (theoretical)<\/li><li>Danaparoid (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Edoxaban (theoretical)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Enoxaparin (theoretical)<\/li><li>Eptifibatide (theoretical)<\/li><li>Fondaparinux (theoretical)<\/li><li>Fosinopril (established)<\/li><li>Heparin (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Lisinopril (established)<\/li><li>Moexipril (established)<\/li><li>Nadroparin (theoretical)<\/li><li>Nitroglycerin (probable)<\/li><li>Parnaparin (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Perindopril (established)<\/li><li>Phenindione (theoretical)<\/li><li>Phenprocoumon (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Reteplase, Recombinant (theoretical)<\/li><li>Reviparin (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Streptokinase (theoretical)<\/li><li>Sulfinpyrazone (theoretical)<\/li><li>Tenecteplase (theoretical)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (theoretical)<\/li><li>Tirofiban (theoretical)<\/li><li>Trandolapril (established)<\/li><li>Treprostinil (theoretical)<\/li><li>Urokinase (theoretical)<\/li><li>Warfarin (theoretical)<\/li><\/ul>"}}},"5":{"id":"20930-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia, Cardiac tamponade, Laceration - injury, Myocardial rupture, Pericardial effusion, Pericarditis<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (5%)<\/li><li><b>Hematologic:<\/b>Bleeding<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Cerebral herniation, Cerebrovascular accident (1.6%), Intracranial hemorrhage (0.4 to 1.3%), Ischemic stroke, Seizure<\/li><li><b>Respiratory:<\/b>Pleural effusion, Pulmonary edema<\/li><li><b>Other:<\/b>Angioedema, Orolingual<\/li><\/ul>"},"6":{"id":"20930-s-6","title":"Drug Name Info","sub":{"0":{"id":"20930-s-6-17","title":"US Trade Names","mono":"<ul><li>Activase<\/li><li>Cathflo Activase<\/li><\/ul>"},"2":{"id":"20930-s-6-19","title":"Class","mono":"<ul><li>Thrombolytic<\/li><li>Tissue Plasminogen Activator<\/li><\/ul>"},"3":{"id":"20930-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"20930-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"20930-s-7","title":"Mechanism Of Action","mono":"Alteplase (recombinant) is a tissue plasminogen activator (TPA) manufactured by DNA technology. It enhances the conversion of plasminogen to plasmin by binding to fibrin, initiating fibrinolysis with limited systemic proteolysis.<br\/>"},"9":{"id":"20930-s-9","title":"Administration","mono":"<ul><li><b>Instillation route<\/b><br\/><ul><li>(intracatheter) dilute Cathflo(R) Activase(R) with Sterile Water for Injection to a final concentration of 1 mg\/mL<\/li><li>(intracatheter) do not shake Cathflo(R) Activase(R), mix by gently swirling<\/li><li>(intracatheter) attempt to aspirate blood after 30 minutes of dwell time; if successful, aspirate 4 to 5 mL of blood (3 mL in patients less than 10 kg) and gently irrigate the catheter with NS; if unsuccessful, allow to dwell 90 more minutes and repeat<\/li><li>(intracatheter) if still unsuccessful after 120 minutes, a second dose of Cathflo(R) Activase(R) may be instilled<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>Reconstitute to a concentration of 1 mg\/mL with provided sterile water for injection without preservatives and administer within 8 hours.<\/li><li>Immediately before administration, reconstituted solution may be further diluted to a concentration of 0.5 mg\/mL with NS or D5W using polyvinyl chloride bags or glass vials.<\/li><li>Do not shake; gently swirl or slowly invert to mix.<\/li><li>Do not mix with other medications.<\/li><\/ul><\/li><\/ul>"},"10":{"id":"20930-s-10","title":"Monitoring","mono":"<ul><li>acute ischemic stroke: improved neurological status may indicate efficacy<\/li><li>acute myocardial infarction: evidence of cardiac reperfusion may indicate efficacy<\/li><li>catheter occlusion: restoration of catheter function is indicative of efficacy<\/li><li>pulmonary embolism: improvement in signs and symptoms may indicate efficacy<\/li><li>signs and symptoms of bleeding, especially at arterial puncture sites<\/li><li>acute ischemic stroke: blood pressure, frequently; during and after administration<\/li><\/ul>"},"11":{"id":"20930-s-11","title":"How Supplied","mono":"<ul><li><b>Activase<\/b><br\/>Intravenous Powder for Solution: 50 MG, 100 MG<br\/><\/li><li><b>Cathflo Activase<\/b><br\/>Intravenous Powder for Solution: 2 MG<br\/><\/li><\/ul>"},"12":{"id":"20930-s-12","title":"Toxicology","sub":[{"id":"20930-s-12-31","title":"Clinical Effects","mono":"<b>THROMBOLYTICS<\/b><br\/>OVERDOSE: Symptoms are likely an extension of adverse effects. ADVERSE EFFECTS: Most common complication observed with thrombolytic therapy is hemorrhage, particularly from puncture sites; severe internal bleeding has occurred. Bleeding can occur at any site (eg, CNS, GI, GU, skin, mucosa). Other effects can include: nausea and vomiting, hallucinations, agitation, confusion, depression, bronchospasm, hyperthermia, chills, back or abdominal pain, leukocytosis, platelet activation, emboli, arterial occlusions, reperfusion dysrhythmias, cerebrovascular accidents, hypotension, hemopericardium, Guillain-Barre syndrome, renal dysfunction, hepatitis, and cutaneous or allergic reactions.<br\/>"},{"id":"20930-s-12-32","title":"Treatment","mono":"<b>THROMBOLYTICS<\/b><br\/><ul><li>Decontamination: Not required.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Hemorrhage: Give fresh frozen plasma and\/or cryoprecipitate, and packed RBCs for active bleeding.<\/li><li>Hypotensive episode: IV 0.9% NaCl, blood products if bleeding, dopamine, or norepinephrine.<\/li><li>Seizure: IV benzodiazepines, barbiturates.<\/li><li>Aminocaproic acid: Not documented as an antidote for streptokinase, but may be considered in an emergency. Dose - 16 to 20 mL (4 to 5 g) of Amicar(R) Injection in 250 mL of diluent, administered by infusion during the first hour of treatment, then a continuing infusion at a rate of 4 mL (1 g) per hour in 50 mL of diluent. Usually continued for about 8 hours or until the bleeding has been controlled.<\/li><li>Aprotinin: In several cases, aprotinin has been used to control bleeding following streptokinase administration.<\/li><li>Monitoring of patient: Monitor vital signs, CBC, renal function and hepatic enzymes in symptomatic patients.  Monitor urine and stool for occult blood.  Monitor hematocrit, hemoglobin, partial thromboplastin time, prothrombin time\/INR, platelet count, and fibrinogen in patients with serious bleeding.<\/li><\/ul>"},{"id":"20930-s-12-33","title":"Range of Toxicity","mono":"<b>THROMBOLYTICS<\/b><br\/>TOXICITY: Varies with agent. A minimum toxic dose has not been established. <br\/>"}]},"13":{"id":"20930-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should notify healthcare provider of recent trauma or surgery prior to drug administration.<\/li><li>Instruct patient to report signs\/symptoms of bleeding, new or increasing chest pain, or new or increasing dyspnea.<\/li><li>Advise patient bedrest will be required during and after drug administration. Caution patient to avoid injury until drug effects subside.<\/li><\/ul>"}}}